Quick Answer
CytomX Therapeutics, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $76.20 million for the year ending 2025.
- CytomX Therapeutics, Inc. showed a decrease of -44.8% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from CytomX Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $11.65 million | Q2 2017: $8.75 million | Q3 2017: $24.14 million | Q4 2017: $27.07 million | Q1 2018: $14.18 million | Q2 2018: $21.34 million | Q3 2018: $12.51 million | Q4 2018: $11.47 million | Q1 2019: $29.49 million | Q2 2019: $9.01 million | Q3 2019: $10.71 million | Q4 2019: $8.28 million | Q1 2020: $49.59 million | Q2 2020: $16.61 million | Q3 2020: $17.79 million | Q1 2021: $15.97 million | Q2 2021: $16.29 million | Q3 2021: $17.59 million | Q1 2022: $9.04 million | Q2 2022: $12.85 million | Q3 2022: $11.15 million | Q1 2023: $23.50 million | Q2 2023: $24.72 million | Q3 2023: $26.38 million | Q1 2024: $41.46 million | Q2 2024: $25.12 million | Q3 2024: $33.43 million | Q1 2025: $50.92 million | Q2 2025: $18.66 million | Q3 2025: $5.96 million.
- Over the full 10 years of available data (2016 to 2025), CytomX Therapeutics, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 493.2%.
- Historical annual values: Fiscal year 2025: $76.20 million | Fiscal year 2024: $138.10 million | Fiscal year 2023: $101.21 million | Fiscal year 2022: $53.16 million | Fiscal year 2021: $37.31 million | Fiscal year 2020: $100.36 million | Fiscal year 2019: $57.49 million | Fiscal year 2018: $59.50 million | Fiscal year 2017: $71.62 million | Fiscal year 2016: $12.85 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: